Skip to main content

Table 2 Anti-tumor activity of anlotinib plus TP regime in the first-line therapy for ESCC

From: A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

Best responses

All patients (n = 46)

CR

4 (8.7%)

PR

31 (67.4%)

SD

7 (15.2%)

PD

NE

0

4 (8.7%)

ORR

35 (76.1%, 61.2–87.4%)

DCR

42 (91.3%, 79.2–97.6%)

  1. Data are presented as n (%) or n (%, 95% confidence interval)
  2. CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, DCR disease control rate
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us